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determination of leptin in serum and breast milk
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The preparation of a disposable electrochemical
immunosensor for the quantiﬁcation of the hormone leptin
is described in this work.
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20A disposable electrochemical immunosensor for the
determination of leptin in serum and breast milk
Irene Ojeda, Mar´ıa Moreno-Guzma´n, Araceli Gonza´lez-Corte´s, Paloma Ya´~nez-
Sede~no* and Jose´ M. Pingarro´n
The preparation of a disposable electrochemical immunosensor for the quantiﬁcation of the hormone
leptin is described in this work. The preparation approach involved immobilization of a speciﬁc
biotinylated anti-leptin antibody on the surface of streptavidin-functionalized magnetic beads (Strept-
MBs) and a sandwich-type immunoassay involving the target analyte, monoclonal anti-leptin, and IgG
labeled with alkaline phosphatase (AP-IgG). The electrochemical transduction step was accomplished by
trapping the MBs bearing the immunoconjugates onto screen-printed carbon electrodes (SPCEs) by
means of an Nd magnet and measuring the electrochemical oxidation of the 1-naphthol generated in
the AP enzyme reaction upon 1-naphthyl phosphate (1-NPP) additions by diﬀerential pulse voltammetry
(DPV). A calibration plot with a linear range between 5 and 100 pg mL1 as well as a detection limit of
0.5 pg mL1 (3sb/m) were achieved. This value is more than 27 times lower than that reported in the
only voltammetric immunosensor for leptin described in the literature until now. The usefulness of the
immunosensor was demonstrated by analyzing diﬀerent types of real samples: human serum, infant
powdered milk, and breast milk from a nursing mother with two months of breastfeeding.25
30
35
40
451 Introduction
Leptin is a 16 kDa peptide hormone that plays an important role
in regulating food intake and body composition in mammals.1 It
is mainly released from adipose tissue and thought to act as an
adiposity signal to the brain, promoting anorexia.2,3 The level of
this hormone directly reects energy status4 and appears as a
central link between adiposity, appetite and weight. It seems to
contribute to body weight regulation by controlling food intake
and energy expenditure at the hypothalamic level.5,6 In humans,
leptin is associated with obesity, appetite regulation, energy
expenditure, and reproduction. Normal levels are 3.7–11.1 ng
mL1 in women and 2.0–5.6 ngmL1 inmen, whereas noticeably
higher leptin levels have been observed in obese individuals.7–9 In
mammals, leptin is expressed primarily in white adipose tissue,
although other tissues such as gastric epithelial lining, placenta,
muscle, brain, pituitary, and hypothalamus have also been found
to be sites of leptin expression. The leptin function in the regu-
lation of appetite, energy metabolism and fertility, and in the
maintenance of body weight by acting as a peripheral hormone
‘sensor’ for the size of adipocyte energy (lipid) stores has been
reported.10 Human mammary epithelial cells are able to synthe-
size the hormone, which is also present in breast milk suggesting
that leptin in human milk might be involved in the regulation of
postnatal nutrition and growth.11 In fact, it has been claimed thatof Chemistry, University Complutense of
@quim.ucm.es
Chemistry 2013
50breast milk leptin provides protective eﬀects against overweight
in adulthood and it has been proposed as an important factor
that could partially explain the increased risk of obesity of
formula-fed infants with respect to breastfed infants.12Moreover,
although no infant formula contains leptin, this compound
could be added to the formula and delivered through various
feeding methods without loss.13
Analytical methods involving capillary electrophoresis,14,15
immunofunctional assay,16 enzyme-linked immunosorbent
assay (ELISA),17 radioimmunoassay18–22 and western blotting23–25
techniques have been used to determine human leptin. Various
ELISA kits based on the use of peroxidase-labelled immunore-
agents and colorimetric detection by addition of hydrogen
peroxide in the presence of 3,30,5,50-tetramethylbenzidine
(TMB) are commercially available. The analytical characteristics
of some representative examples of these methods are
summarized in Table 1. Apart from these, a nanoarray protein
chip involving a sandwich uorescence immunoassay moni-
tored by total internal reection uorescence microscopy
(TIRFM) was also reported.4 Moreover, a chemiluminescence
enzyme immunoassay (CLEIA) using anti-leptin polyclonal
antibody and alkaline phosphatase, achieving a detection limit
of 0.1 pg mL1, has been reported more recently.26
Regarding electrochemical immunosensors, to the best of our
knowledge, only two congurations have been proposed. One of
the approaches involved the use of a tri(ethylene glycol)-termi-
nated alkanethiol (TEGCnSH)-modied gold electrode on which
the capture antibody was covalently immobilized. Leptin andAnalyst, 2013, xx, 1–8 | 1
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35anti-leptin antibody–alkaline phosphatase were also used and
the square-wave voltammetric oxidation current for p-amino-
phenol as the enzyme product was employed to monitor the
antigen concentration. A linear range for leptin between 100 pg
mL1 and 10 ngmL1, and a detection limit of 13.6 pgmL1 (S/N
¼ 3) were reported.27 The second described conguration con-
sisted of a label-free impedimetric immunosensor. A pyrrole and
pyrrole propylic acid composite was prepared by co-electro-
polymerization in the presence of gold nanoparticles, followed by
the covalent attachment of protein G to capture anti-leptin IgG. A
dynamic range of 10–105 ng mL1 and a detection limit of 10 ng
mL1 in 0.01 M PBS-1% serum solutions were obtained.28
In this work, the development of a disposable electro-
chemical immunosensor for the quantication of leptin in
human serum and milk, including breast milk, is reported. The
immnunosensor design involves the use of screen-printed
carbon electrodes (SPCEs) and functionalized magnetic beads
(MBs), which have been demonstrated to be powerful and
versatile tools for the development of eﬃcient immunosensing
platforms.29 Biotinylated polyclonal anti-leptin antibodies were
immobilized on streptavidin-modied MBs and a sandwich
type immunoassay involving leptin, monoclonal anti-leptin,
and alkaline phosphatase (AP)-labeled IgG was carried out. The
MBs bearing the resulting bioconjugates were trapped on the
surface of the SPCE with a small magnet. This simple meth-
odology allowed measurements to be carried out with small
solution volumes giving rise to a high concentration of reagents
on the transducer surface and, therefore, enabling the
achievement of low detection limits. The quantication of lep-
tin was accomplished by DPV monitoring of 1-naphthol formed
in the enzyme reaction catalyzed by AP upon 1-naphthyl phos-
phate addition. The packing of MBs on the SPCE surface also
implied that the enzyme reaction product was generated very
close to the electrode surface, thus allowing the steady-state to
be reached rapidly (which implies faster measurements), and
minimizing diﬀusion limitations of the electroactive species.40
45
502 Experimental
2.1 Apparatus and electrodes
The electrochemical measurements were performed with an
Autolab PGSTAT 12 potentiostat equipped with the General
Purpose Electrochemical System (GPES) 4.7 soware (EcoChe-
mie B.V.). An Optic Ivymen System provided with stirring and
temperature control, a magnetic separator (DynaMagn, Invi-
trogen Dynal), a Vortex homogenizator (Heidolph), and a
magnetic stirrer from P-Selecta, Agimatic, were also used.
Screen-printed carbon electrodes (SPCEs) consisting of a carbon
working electrode 4 mm in diameter, a Ag pseudo-reference
electrode, and a carbon counter electrode were purchased from
DropSens. All the electrochemical measurements were per-
formed at room temperature.Fig. 1 Schematic display of the diﬀerent steps involved in the preparation
and functioning of the AP-IgG/anti-leptin/leptin/anti-leptin-Biotin/Strept-MB
immunosensor.
552.2 Reagents and solutions
Mouse monoclonal anti-leptin (anti-leptin, clone 3G1-1C9, 500
mg mL1, Sigma), rabbit polyclonal human anti-leptinThis journal is ª The Royal Society of Chemistry 2013biotinylated (anti-leptin-Biotin, 1000 mg mL1, LifeSpan),
human leptin (1 mg mL1, Sigma), and anti-mouse IgG (Fc
specic, from goat) labeled with alkaline phosphatase (AP-IgG,
Sigma) were the immunoreagents used. Magnetic microbeads
functionalized with streptavidin (Strept-MBs, 10 mg mL1,
Dinabeads streptavidin, Invitrogen Dynal, 10 mg mL1), bovine
serum albumin (BSA, Type VH, Gerbu), and D-Biotin (Gerbu)
were also employed. Adrenocorticotropin (ACTH, Genway
Biotech), human growth hormone (hGH, Sigma), progesterone
(Sigma), prolactin (Immunometrics), cortisol (Sigma) and 17 b-
estradiol (Sigma) were other hormones tested in the interfer-
ence study. 1-Naphthyl phosphate monosodium salt mono-
hydrate (1-NPP, Sigma), Trizma (tris(hydroxymethyl)
aminomethane, Sigma), MgCl2 (Panreac), EDTA (Panreac), and
Tris–HCl (Scharlau) were also utilized. From these, a 10 mM
Tris–HCl buﬀer solution of pH 7.4, containing also 2 mM NaCl
and 1 mM EDTA (Tris-washing), and a 5 mM Tris–HCl buﬀer
solution of pH 7.4, containing 1MNaCl and 0.5 mMEDTA (Tris-
coating), were prepared. A 50 mM Tris–HCl buﬀer solution of
pH 7.4, containing 140 mM NaCl and 1 mM MgCl2 (Tris-
binding), was also employed to prepare biotin solutions. Tris-
binding buﬀer solutions containing 5% or 2% BSA were used to
prepare leptin, anti-leptin or AP-IgG solutions (5, 5, and 2%
BSA, respectively). 1-NPP solutions and the AP enzyme reaction
working medium were prepared with 0.1 M Trizma buﬀer
solution of pH 9 containing 1 mMMgCl2 (Trizma buﬀer). Three
diﬀerent types of samples were analyzed: human serum from
Sigma (S-7397) spiked with leptin at 5.0, 25, 50 and 100 ng mL1
concentration levels; an infant formula consisted of powdered
milk from Blemil (Blemil Plus 1 Forte) which was spiked at the
1.0 and 7.0 ng mL1 leptin concentration levels; and breast milk
containing an unknown leptin concentration which was
obtained from a nursingmother of twomonths of breastfeeding
with BMI ¼ 27.3. Water used was obtained from a purication
Millipore Milli-Q system.Analyst, 2013, xx, 1–8 | 3
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552.3 Procedures
2.3.1 Preparation of the AP-IgG/anti-leptin/leptin/anti-lep-
tin-Biotin/Strept-MB conjugates and determination of leptin. A
scheme of the diﬀerent steps involved in the preparation and
functioning of the AP-IgG/anti-leptin/leptin/anti-leptin-Biotin/
Strept-MB immunosensor is depicted in Fig. 1. In detail, 2 mL of
the Strept-MB suspension were transferred into a 1.5 mL Eppen-
dorf tube andwashed twice with the washing buﬀer. Each washing
step consisted of a re-suspension of the MBs in the washing
solution and gentle stirring for 1 min (up to homogenization)
followed by separation with the magnet for 2 min and removal of
the solution. Next, 50 mL of a 5 mg mL1 anti-leptin-Biotin solution
were added and incubated for 45 min. All the incubation steps
were performed in an incubator at 37 C and 950 rpm and two
washing steps were applied in all cases aer the incubation
period. Thereaer, 50 mL of a 2050 mMBiotin solution were added
allowing incubation for 30min. Further, 50 mL of leptin solution of
variable concentration, 50 mL of a 0.5 mg mL1 anti-leptin solution
and 50 mL of a 1 : 1000 AP-IgG solution were sequentially added
with a 45 min incubation period aer each addition. Aer the
preparation of the immunoconjugates, the AP-IgG/anti-leptin/
leptin/anti-leptin-Biotin/Strept-MBs were re-suspended in 45 mL of
Trizma buﬀer of pH 9, and transferred onto the surface of the
SPCE. This was done by keeping the SPCE horizontal and placing a
neodymiummagnet on the bottom part of the electrode to localize
in a reproducible way the MBs onto the working surface, thus
avoiding variations in the bead layer thickness or spreading area of
the electrode surface between diﬀerent measurements. Finally, 5
mL of 0.05M 1-naphthyl phosphate solution were deposited on the
modied electrode and allowed to stand for 5 min. Diﬀerential
pulse voltammograms (step potential ¼ 50 mV; modulation time
¼ 50 ms; scan rate ¼ 50 mV s1) were then recorded in the 0.15
to +0.75 V potential window.
2.3.2 Analysis of the diﬀerent samples. As mentioned
above, solid lyophilized human serum was spiked with leptin at
5, 25, 50 and 100 ng mL1 concentration levels. The solid serum
was reconstituted in 1 mL of Tris buﬀer solution of pH 7.2 also
containing 5% BSA by mixing up total dissolution. Thereaer, a
1 : 1000 dilution with the same buﬀer plus 5% BSA solution was
performed. On the other hand, Blemil plus 1 forte infant
formula for newborn from birth to 6months of age consisting of
powdered milk and spiked with 1 or 7 ng mL1 leptin was also
analyzed. 150 mg of the sample were dissolved in 1 mL of
distilled water at 40 C and the resulting solution was treated
similarly to breast milk. Thereaer, 1 : 100 or 3 : 1000 dilution,
respectively, was made with Tris buﬀer of pH 7.2 also contain-
ing 5% BSA. All the prepared sample solutions were analyzed by
following the protocol described in Section 2.3.1. Finally, breast
milk from a nursing mother in the second month of lactation
was also analyzed. The sample was homogenized by manual
and ultrasonic stirring and centrifuged at 2000 rpm for 20 min
at 4 C to separate cream. A 1 : 100 dilution with Tris buﬀer of
pH 7.2 containing 5% BSA was carried out. Validation of the
obtained results in the analysis of leptin in breast milk was
accomplished by comparing with those provided by an ELISA
kit for human leptin from Abnova (Catalog Number KA 06494 | Analyst, 2013, xx, 1–8Version:02). The protocol indicated in the suppliers directions
consisted, in brief, of pipetting standards or samples into the
anti-leptin coated-well plates and leaving an incubation time of
1 h. Then, biotinylated anti-human leptin was added and
allowed to stand for 30 min. Aer this, HRP–streptavidin was
also pipetted into the well plates, leaving 30 min, and colour
development was achieved by addition of TMB substrate solu-
tion. Finally, aer 20 min, an acid “stop solution” was added,
and the absorbance was measured at 450 nm.3 Results and discussion
The fundamentals of the diﬀerent steps involved in the
immunoreaction occurring on the functionalized MBs, the
transfer of MBs bearing the immunoconjugates on the SPCE
surface and the voltammetric transduction strategy employed
were schematically depicted in Fig. 1. Anti-leptin-Biotin anti-
bodies were attached to Strept-MBs and a blocking step with
biotin of the remaining active sites in the functionalized MBs
was accomplished. Thereaer, the anti-leptin-Biotin/Strept-MBs
were incubated in the analyte solution and the sandwich
immunoassay was completed by attachment of anti-leptin to
the MB-conjugate. Then, anti-leptin/leptin/anti-leptin-Biotin/
Strept-MBs were incubated in a AP-IgG solution in order to link
the detection antibody to the sandwich immunoconjugates. The
modied MBs were subsequently transferred onto the SPCE
surface where they were magnetically entrapped and, upon
addition of 1-NPP as the AP-substrate, the generated 1-naphthol
was electrochemically oxidized at the SPCE and the DPV
response was used for leptin quantication.3.1 Optimization of experimental variables
All the variables concerning the preparation of the immuno-
sensor and aﬀecting its electrochemical performance were
optimized. The analytical signals were the peak currents
measured by diﬀerential pulse voltammetry between 0.15 and
+0.75 V for the 1-naphthol generated in the enzyme reaction
with alkaline phosphatase. The amount of anti-leptin-Biotin
immobilized on the Strept-MBs was evaluated by preparing
diﬀerent immunosensors incubated with MBs in solutions
containing 2 to 20 mg mL1 anti-leptin-Biotin. 2 mL MBs, 2050
mM Biotin, 1 mg mL1 anti-leptin, 0, 0.05 and 5 ng mL1 leptin
concentrations, 1 : 5000 AP-IgG and 5 mM 1-NPP were used in
these assays. Fig. 2a shows that the diﬀerence between the
currents measured for 5 and 0.05 ng mL1 was larger than that
measured for a 5 mg mL1 anti-leptin-Biotin loading which
implies a larger sensitivity in the subsequent determination of
leptin. Moreover, it is also apparent that for this anti-leptin-
Biotin concentration the unspecic adsorption (the signal
measured for 0 ng mL1 leptin) was very low. Therefore, this
loading was selected for further work. The inuence of the anti-
leptin antibody concentration used to build the sandwich
conguration was checked over the 0.25–2 mg mL1 range
(Fig. 2b). Themeasured peak current values for 5 ngmL1 leptin
were similar to those for 0.5 and 1 mg mL1 anti-leptin indi-
cating that saturation was reached for 0.5 mg mL1 anti-leptin.This journal is ª The Royal Society of Chemistry 2013
Table 2 Optimization of the working variables involved in the preparation of
AP-IgG/anti-leptin/leptin/anti-leptin-Biotin/Strept-MB immunosensors
Variable Tested range Selected value
Anti-leptin-Biotin, mg mL1 2–20 5
Anti-leptin, mg mL1 0.25–2 0.5
AP-IgG, dilution factor 1000–20 000 1000
1-Naphthyl phosphate, mM 0.05–50 5
Time for hydrolysis 0–8 5
Fig. 2 Eﬀect of anti-leptin-Biotin (a) and anti-leptin (b) loadings and AP-IgG
dilution factor (c) on the DPV responses obtained for 0, 0.05 and 5 ngmL1 leptin.
See text for the other experimental conditions.
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40Probably, the big increase in the current observed for 2 mg mL1
anti-leptin, which is a much higher concentration than that
required to saturate the antigen, was due to the formation of an
antibody-double layer. According to these observations, 0.5 mg
mL1 anti-leptin was selected for further work. Larger peak
currents were obtained for the lower AP-IgG dilution factors
assayed (Fig. 2c) and no signicant diﬀerences in current were
observed when smaller dilution factors were applied. Therefore,
a 1 : 1000 AP-IgG dilution was used for preparation of the
immunosensor.
As it is described in the Experimental section, Biotin and BSA
were used as the blocking agents to minimize unspecic
adsorptions. The concentration of these reagents used in the
diﬀerent steps of the immunosensor preparation was also
optimized. Firstly, blocking of the remaining free sites on the
Strept-MBs aer anti-leptin-Biotin binding was performedFig. 3 Eﬀect of the 1-NPP concentration (a) and the time elapsed to allow hydroly
anti-leptin-Biotin/Strept-MB immunosensor.
This journal is ª The Royal Society of Chemistry 2013using a Biotin solution. The results obtained (not shown)
revealed that eﬀective blocking was reached from Biotin
concentrations higher than 1500 mM and, accordingly, a 2050
mMBiotin solution was employed for this purpose. Moreover, as
it is described in Section 2.2, the leptin, anti-leptin and AP-IgG
solutions were prepared in buﬀer solutions containing opti-
mized BSA percentages (5, 5, and 2% BSA, respectively). This
procedure allowed the smallest current values for control
solutions without analytes to be obtained. Under these condi-
tions unspecic adsorptions represented only 7.5% of the peak
current obtained for 5 ng mL1 leptin.
The inuence of 1-naphthyl phosphate concentration on the
DPV responses for 5 ng mL1 leptin was also evaluated. Fig. 3a
shows that the ip values increased with the substrate concen-
tration up to 5 mM exhibiting a sharp decrease for larger
concentrations most likely due to the electrode fouling as a
consequence of the electrochemical reaction product electro-
polymerization. Accordingly, 5 mM 1-NPP was selected to
guarantee that the enzyme reaction rate depended only on the
enzyme concentration. This enzyme reaction was performed at
pH 9.0, which corresponded to the optimum AP activity.30
Finally, the period of time that the enzyme hydrolysis reaction
was let to proceed was also checked (Fig. 3b). As can be seen, the
DPV response levelled oﬀ for 5 min.
All the optimized working variables and the corresponding
selected values are summarized in Table 2.3.2 Analytical gures of merit for the determination of leptin
with the AP-IgG/anti-leptin/leptin/anti-leptin-Biotin/Strept-
MB immunosensor
Fig. 4 shows the calibration plot constructed for leptin determi-
nation by DPV under the optimized conditions stated above. Thesis (b) on the DPV response for 5 ng mL1 leptin at the AP-IgG/anti-leptin/leptin/
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Fig. 4 Calibration plot constructed for leptin by DPV at the AP-IgG/anti-leptin/leptin/anti-leptin-Biotin/Strept-MB immunosensor. Diﬀerential pulse voltammograms
recorded for 1–100 pg mL1 leptin.
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40linear dynamic range extended between 5 and 100 pg mL1 (r2 ¼
0.982). Taking into account both normal and abnormally high
levels of leptin in serum, this range allowed dilution of real
samples to be performed in a factor of approximately 1000 which
was necessary to maintain matrix eﬀects negligible. The slope
value of the linear portion in the calibration plot was 14.7  1.2
mA pg1 mL1. The limit of detection was calculated according to
the 3sb/m criterion, where sb was estimated as the standard
deviation from ten successive measurements of the peak current
measured for the lowest leptin concentration of the linear part in
the calibration plot and m was the slope of such a linear portion
mentioned above. The calculated value was 0.5 pgmL1, which is
remarkably lower than those reported previously with all the
immunoassays listed in Table 1. Furthermore, it is more than 27
times lower than that obtained with the only voltammetric
immunosensor for leptin described in the literature until now,27
and twenty thousand times lower than that achieved with the
label-free impedimetric immunosensor.28
The reproducibility of the DPV responses was evaluated by
carrying out measurements with a diﬀerent immunosensor per
assay for: (a) 5, 25 and 100 pg mL1 leptin on the same day, and
(b) 100 pg mL1 on diﬀerent days. The relative standard devi-
ation (RSD) values obtained were: (a) 6.0% (n¼ 10), 7.4% (n¼ 6)
and 6.7% (n ¼ 6), respectively, and (b) 4.8% (n ¼ 7). These
results demonstrated the suitability of the immunosensorFig. 5 Control chart constructed to evaluate the storage stability of anti-leptin-
Biotin/Strept-MB conjugates. Each point corresponds to the mean value of three
successive measurements for 100 pg mL1 leptin.
6 | Analyst, 2013, xx, 1–8preparation procedure. On the other hand, the storage stability
of the anti-leptin-Biotin/Strept-MB bioconjugates was checked
by placing the same amount of conjugate, prepared on the same
day, in diﬀerent Eppendorf tubes containing 50 mL of binding
buﬀer and 0.01% Tween 20 and stored in a refrigerator at 8 C.
The corresponding AP-IgG/anti-leptin/leptin/anti-leptin-Biotin/
Strept-MB immunosensors were then prepared from each
conjugate and used to measure the DPV response for 100 pg
mL1 leptin. Fig. 5 shows the control chart constructed setting
the central value as the mean value of ten diﬀerent measure-
ments carried out on the rst working day, and the upper and
lower limits of control as three times the standard deviation of
the central value (3 s). As it can be seen, the DPV responses
obtained with the immunosensors prepared with the stored
immunoconjugates remained inside the control limits for more
than onemonth (no longer periods were checked). These results
indicated a high storage stability of the antibody-modied MB
conjugates leading to the possibility of their preparation and
storage until the immunoassays have to be carried out.Fig. 6 Diﬀerential pulse voltammograms recorded at the AP-IgG/anti-leptin/
leptin/anti-leptin-Biotin/Strept-MB immunosensor for 10 pg mL1 leptin (1), 0 pg
mL1 leptin (2), and for physiological concentrations of potential interfering
compounds: 250 ngmL1 cortisol (3); 60 pgmL1 ACTH (4); 1.5 ngmL1 estradiol
(5); 200 ng mL1 progesterone (6); 50 ng mL1 hGH (7), and 200 ng mL1
prolactin (8).
This journal is ª The Royal Society of Chemistry 2013
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153.3 Cross-reactivity
The determination of leptin in biological uids or in breast milk
implies that other hormones may be present in these real
samples. Therefore, various compounds were tested as poten-
tial interferences for the developed immunosensor response to
leptin. These compounds were: ACTH, hGH, progesterone,
prolactin, cortisol and estradiol. Fig. 6 compares the DP vol-
tammograms recorded for 10 pg mL1 leptin (voltammogram 1)
and in the absence of leptin (voltammogram 2) with those
obtained for the potential interfering compounds at the
concentration values corresponding to physiological levels for
each hormone. As it can be seen, all the tested compounds
exhibited a much smaller voltammetric signal compared to that
of the analyte, which was similar to that obtained for the blank
solution. These results suggested that the measured signals
corresponded to non-specic adsorptions on the Strept-MBs
and that none of the checked compounds produced interfer-
ence on the voltammetric response for leptin.20
25
30
35
403.4 Determination of leptin in human serum, an infant
formula and breast milk samples
The analytical usefulness of the immunosensor was demon-
strated and evaluated by determining leptin in three diﬀerent
samples: a human serum spiked with leptin at 5.0, 25, 50 and
100 ng mL1 concentration levels, a commercial infant formula
(powdered milk) spiked with 1.0 and 7.0 ng mL1 leptin, and
breast milk from a nursing mother in the second month of
lactation. The employed protocols are described in Section
2.3.2. Firstly, in order to evaluate the inuence of a possible
matrix eﬀect in serum, samples spiked with 100 ng mL1 leptin
were reconstituted in Tris buﬀer solution of pH 7.2 containing
5% BSA and diluted with the same buﬀer solution. The results
obtained (not shown) revealed that the peak current measured
from a 1 : 10 diluted serum was 24% lower than that recorded
for a leptin standard solution, thus revealing the existence of a
signicant matrix eﬀect from the sample components.
However, no signicant diﬀerences between the ip values for the
sample and the standard solution were apparent from a 1 : 100
dilution factor. Considering the sample spiking concentration
levels and the linear dynamic range of the calibration plot, a
1 : 1000 sample dilution factor, where the matrix eﬀect wasTable 3 Determination of leptin in spiked human serum and infant formula with
the AP-IgG/anti-leptin/leptin/anti-leptin-Biotin/Strept-MB immunosensor
Leptin, ng mL1 Leptin founda, ng mL1 Recovery, %
Human serum
5.0 4.8  0.2 96  5
25 25.5  1.3 102  5
50 51  3 101  6
100 96  2 96  2
Infant formula
1.0 0.98  0.08 98  8
7.0 7.2  0.3 102  4
a Mean value  ts/On.
This journal is ª The Royal Society of Chemistry 2013
45certainly negligible, was used for the analyses. Under these
conditions, a calibration graph for leptin, similar to that
obtained for leptin standard solutions, was constructed with a
slope value for its linear portion of 13.5  0.4 mA pg1 mL1,
which was not statistically diﬀerent (calculated Student's t-value
1.057 < ttab 2.015 for a signicance level of 0.05) than that the
slope value obtained with leptin standards given above (14.7 
1.2 mA pg1 mL1). Therefore, the quantication of leptin in
serum samples was accomplished by interpolation of the
measured peak current into the calibration plot constructed
with leptin standard solutions. The results obtained are
summarized in Table 3. Recoveries ranged between 96 and
102% with RSD values of 2.9, 2.7, 3.0 and 1.8 (n ¼ 3) for 5.0, 25,
50 and 100 ng mL1 leptin, respectively.
Moreover, the infant formula Blemil plus 1 forte for newborn
from birth to 6 months old spiked with 1.0 and 7.0 ng mL1
leptin was also analyzed. The experimental procedure was
described in Section 2.3.2 and, in this case, involved a sample
dilution of 1 : 100 or 3 : 1000, respectively, with the Tris buﬀer
of pH 7.2 containing 5% BSA. These dilution factors guaranteed
a negligible matrix eﬀect and that the measured current fell
within the linear range of the calibration plot constructed with
leptin standard solutions. Table 3 shows that recoveries of 98%
and 102% with RSD values of 5.9% and 2.9% (n ¼ 4) were
obtained for 1 and 7 ng mL1 leptin, respectively. Finally, breast
milk from a nursing mother in the second month of lactation
was analyzed. The experimental procedure described in Section
2.3.2 implies a 1 : 100 dilution factor with the same buﬀer
solution (considering that the content of leptin in this kind of
milk is between 0.11 and 4.97 ng mL1).31 In this case, in order
to avoid the matrix eﬀect of this very complex sample, the
standard additions method was used for the analyte quanti-
cation (using a diﬀerent immunosensor for each point of the
standard additions plot). The mean leptin (n¼ 3) concentration
found was 2.6  0.1 ng mL1, which falls within the above
mentioned concentration range. This result was compared with
that obtained by using the Abnova ELISA kit for human leptin
following the protocol described in Section 2.3.2. The mean
leptin concentration obtained (n ¼ 3) was 2.9  0.5 ng mL1.
Both mean values were statistically compared by applying
Student's t-test. As the texp value, 2.548, was lower than the
tabulated t value (2.776), no signicant diﬀerences were found
between both results at a signicance level of 0.05.
According to all the obtained results, it can be concluded that
the developed immunosensor is useful for the determination of
leptin at the required concentration levels in diﬀerent types of
relevant samples such as human serum and breast milk.50
554 Conclusions
A novel magnetoimmunosensor for the determination of the
hormone leptin, involving the use of functionalized magnetic
beads, a sandwich-type immunoassay and diﬀerential pulse
voltammetric transduction at screen-printed carbon electrodes,
was developed. The magnetoimmunosensor exhibits an excel-
lent analytical performance in terms of sensitivity, with a much
lower detection limit than those reported for diﬀerent availableAnalyst, 2013, xx, 1–8 | 7
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45immunoassays, selectivity, reproducibility of the measurements
and storage stability of the prepared immunoconjugates.
Furthermore, the immunosensor demonstrated to possess a
high analytical versatility because it is suitable to quantify leptin
in a variety of real samples such as human serum, infant
formula or breast milk. Therefore, the immunosensor appears
to be a useful analytical tool to face up relevant problems
regarding obesity and related aspects with it.
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